Roche Touts Safety Profile For NMOSD Drug Satralizumab
Approvals Sought For Rare Disorder
With Alexion's Soliris already approved, and Viela's inebilizumab within touching distance of an FDA green light, Roche is highlighting the safety profile of its investigational neuromyelitis optica spectrum disorder drug satralizumab.
